



23. The method according to claim 22 wherein said fungus is *Cryptococcus neoformans*.

24. The method according to claim 23 wherein said host is a mammal.
25. The method according to claim 24 in which said mammal is a human.
26. The method according to claim 24 in which said composition is administered to said human by parenteral means.
27. The method according to claim 24 in which said composition is administered topically to said human.
28. The method according to claim 25 in which said composition is administered intravenously to said human.
29. The method according to claim 25 in which said active ingredient is administered in a suppository inserted in said host.
30. The method according to claim 24 in which said composition is administered to said mammal by parenteral means.
31. The method according to claim 24 in which said composition is administered topically to said mammal.
32. The method according to claim 24 in which said composition is administered intravenously to said mammal.
33. The method according to claim 24 in which said composition is administered in a suppository inserted in said mammal.
34. The method according to claim 24 wherein said mammal is infected systematically with *Cryptococcus neoformans*.
35. The method according to claim 24 wherein the epidermis of said mammal is infected with *Cryptococcus neoformans*.
36. The method according to claim 31 wherein said carrier is selected from the group consisting of a water-and-oil emulsion, petrolatum, mineral oil, a moisturizer, and a solubilizer.
37. The method according to claim 27 wherein said carrier is selected from the group consisting of a water-and-oil emulsion, petrolatum, mineral oil, a moisturizer, and a solubilizer.
38. The method of claim 31 in which said carrier contains a fragrance.
39. The method of claim 37 in which said carrier contains a fragrance.